Century Therapeutics IncNASDAQ:IPSC
- LAST PRICE1.3350
- TODAY'S CHANGE (%)0.0750 (5.9524%)
- Bid / Lots1.3300/ 8
- Ask / Lots1.3400/ 8
- Open / Previous Close1.2600 / 1.2600
- Day Range
- 52 Week Range
- Volume418,211
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IPSC |
|---|---|---|
| 09:32 ET | 1676 | 1.26 |
| 09:33 ET | 600 | 1.25 |
| 09:37 ET | 1442 | 1.25 |
| 09:39 ET | 100 | 1.29 |
| 09:42 ET | 600 | 1.265 |
| 09:44 ET | 200 | 1.28 |
| 09:46 ET | 600 | 1.26 |
| 09:48 ET | 300 | 1.3 |
| 09:50 ET | 1100 | 1.29 |
| 09:51 ET | 200 | 1.29 |
| 09:53 ET | 1700 | 1.29 |
| 09:55 ET | 200 | 1.3 |
| 09:57 ET | 900 | 1.3 |
| 10:00 ET | 400 | 1.305 |
| 10:02 ET | 1200 | 1.28 |
| 10:04 ET | 300 | 1.29 |
| 10:06 ET | 1981 | 1.29 |
| 10:08 ET | 540 | 1.305 |
| 10:09 ET | 900 | 1.305 |
| 10:13 ET | 810 | 1.305 |
| 10:15 ET | 1000 | 1.305 |
| 10:18 ET | 1308 | 1.305 |
| 10:20 ET | 2007 | 1.3153 |
| 10:22 ET | 11500 | 1.32 |
| 10:24 ET | 200 | 1.33 |
| 10:26 ET | 700 | 1.325 |
| 10:27 ET | 12833 | 1.335 |
| 10:29 ET | 5665 | 1.33 |
| 10:31 ET | 2900 | 1.3301 |
| 10:33 ET | 1200 | 1.325 |
| 10:36 ET | 10350 | 1.3101 |
| 10:38 ET | 1662 | 1.3192 |
| 10:40 ET | 1200 | 1.315 |
| 10:44 ET | 2825 | 1.32 |
| 10:45 ET | 220 | 1.32 |
| 10:47 ET | 900 | 1.325 |
| 10:49 ET | 1600 | 1.325 |
| 10:51 ET | 1000 | 1.325 |
| 10:54 ET | 300 | 1.325 |
| 10:56 ET | 800 | 1.32 |
| 10:58 ET | 100 | 1.325 |
| 11:00 ET | 700 | 1.325 |
| 11:02 ET | 100 | 1.325 |
| 11:03 ET | 800 | 1.32 |
| 11:05 ET | 100 | 1.32 |
| 11:07 ET | 600 | 1.325 |
| 11:12 ET | 698 | 1.32 |
| 11:14 ET | 100 | 1.33 |
| 11:16 ET | 1500 | 1.33 |
| 11:18 ET | 100 | 1.33 |
| 11:20 ET | 1200 | 1.33 |
| 11:21 ET | 200 | 1.33 |
| 11:23 ET | 1960 | 1.33 |
| 11:25 ET | 200 | 1.335 |
| 11:27 ET | 3000 | 1.335 |
| 11:30 ET | 3400 | 1.335 |
| 11:32 ET | 710 | 1.335 |
| 11:34 ET | 8511 | 1.34 |
| 11:36 ET | 12802 | 1.3488 |
| 11:38 ET | 100 | 1.36 |
| 11:39 ET | 900 | 1.36 |
| 11:41 ET | 1900 | 1.3506 |
| 11:43 ET | 900 | 1.355 |
| 11:45 ET | 30104 | 1.36 |
| 11:48 ET | 24314 | 1.365 |
| 11:50 ET | 1800 | 1.365 |
| 11:52 ET | 800 | 1.365 |
| 11:54 ET | 5100 | 1.365 |
| 11:56 ET | 1453 | 1.365 |
| 11:59 ET | 600 | 1.36 |
| 12:01 ET | 1700 | 1.37 |
| 12:06 ET | 246 | 1.37 |
| 12:08 ET | 1000 | 1.365 |
| 12:10 ET | 2500 | 1.37 |
| 12:12 ET | 870 | 1.3695 |
| 12:14 ET | 200 | 1.37 |
| 12:15 ET | 3800 | 1.375 |
| 12:17 ET | 4300 | 1.385 |
| 12:19 ET | 23934 | 1.39 |
| 12:21 ET | 6200 | 1.39 |
| 12:24 ET | 4900 | 1.4 |
| 12:26 ET | 190 | 1.4095 |
| 12:28 ET | 790 | 1.408 |
| 12:30 ET | 2900 | 1.395 |
| 12:32 ET | 29514 | 1.41 |
| 12:35 ET | 700 | 1.4 |
| 12:37 ET | 2100 | 1.41 |
| 12:39 ET | 1200 | 1.405 |
| 12:42 ET | 4774 | 1.425 |
| 12:44 ET | 800 | 1.43 |
| 12:46 ET | 2000 | 1.43 |
| 12:48 ET | 1275 | 1.425 |
| 12:50 ET | 400 | 1.425 |
| 12:51 ET | 350 | 1.425 |
| 12:53 ET | 1200 | 1.43 |
| 12:55 ET | 300 | 1.43 |
| 12:57 ET | 900 | 1.43 |
| 01:00 ET | 200 | 1.43 |
| 01:02 ET | 3300 | 1.425 |
| 01:04 ET | 3500 | 1.405 |
| 01:06 ET | 900 | 1.405 |
| 01:09 ET | 1600 | 1.405 |
| 01:11 ET | 3351 | 1.395 |
| 01:13 ET | 2832 | 1.39 |
| 01:15 ET | 660 | 1.3909 |
| 01:18 ET | 800 | 1.395 |
| 01:20 ET | 300 | 1.395 |
| 01:22 ET | 854 | 1.39 |
| 01:24 ET | 4023 | 1.385 |
| 01:26 ET | 1754 | 1.385 |
| 01:27 ET | 28230 | 1.36 |
| 01:29 ET | 1380 | 1.365 |
| 01:31 ET | 25041 | 1.34 |
| 01:33 ET | 3500 | 1.335 |
| 01:36 ET | 100 | 1.345 |
| 01:38 ET | 800 | 1.345 |
| 01:40 ET | 360 | 1.345 |
| 01:42 ET | 800 | 1.34 |
| 01:44 ET | 100 | 1.3491 |
| 01:45 ET | 2500 | 1.35 |
| 01:47 ET | 100 | 1.35 |
| 01:49 ET | 3800 | 1.3499 |
| 01:51 ET | 300 | 1.35 |
| 01:54 ET | 2400 | 1.35 |
| 01:56 ET | 300 | 1.345 |
| 01:58 ET | 1000 | 1.35 |
| 02:00 ET | 100 | 1.35 |
| 02:02 ET | 800 | 1.35 |
| 02:03 ET | 100 | 1.35 |
| 02:05 ET | 1420 | 1.345 |
| 02:07 ET | 200 | 1.35 |
| 02:09 ET | 700 | 1.35 |
| 02:12 ET | 6023 | 1.345 |
| 02:14 ET | 2101 | 1.34 |
| 02:16 ET | 679 | 1.33 |
| 02:18 ET | 1602 | 1.33 |
| 02:20 ET | 200 | 1.3389 |
| 02:21 ET | 1120 | 1.335 |
Today
Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates, from 5 hours ago by Dow Jones
5 hours ago by Dow JonesPress Release: Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates, from 5 hours ago by Dow Jones
5 hours ago by Dow JonesCentury Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting, from 5 hours ago by Dow Jones
5 hours ago by Dow Jones
Yesterday
Century Therapeutics to Present at Guggenheim's Inaugural Healthcare Innovation Conference, from 7:00AM ET on Monday Nov 04, 2024 by Dow Jones
7:00AM ET on Monday Nov 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Century Therapeutics Inc | 106.7M | -0.7x | --- |
Quantum-Si Inc | 107.9M | -1.2x | --- |
Genelux Corp | 106.0M | -3.0x | --- |
Fibrobiologics Inc | 106.9M | -3.4x | --- |
Invivyd Inc | 107.4M | -0.5x | --- |
Regencell Bioscience Holdings Ltd | 105.7M | -23.4x | --- |
Company Information
Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with unmet medical need. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-102, CNTY-107, CNTY-104, and CNTY-106. Its CNTY-101 is focused on targeting CD19 for relapsed, refractory B-cell lymphoma. CNTY-102 targets CD19 + CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies. CNTY-107 is used of the treatment of solid tumors expressing Nectin-4. CNTY-106 is a multi-specific collaboration program for multiple myeloma.
Contact Information
- Headquarters
- 25 N 38TH STREET, 11TH FLOORPHILADELPHIA, PA, United States 19104
- Phone
- 215-981-4000
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Joseph Jimenez
- President, Chief Executive Officer, Director
- Brent Pfeiffenberger
- Chief Financial Officer
- Morgan Conn
- President - Research and Development
- Hyam Levitsky
- Chief Operations Officer, Head - Early Development
- Adrienne Farid
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $106.7M |
|---|---|
Revenue (TTM) | $2.0M |
Shares Outstanding | 84.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.41 |
EPS | $-2.04 |
Book Value | $3.06 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | 52.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -7,123.02% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
